These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of linagliptin on human immortalized podocytes: a cellular system to study dipeptidyl-peptidase 4 inhibition. Miglio G; Vitarelli G; Klein T; Benetti E Br J Pharmacol; 2017 May; 174(9):809-821. PubMed ID: 28177527 [TBL] [Abstract][Full Text] [Related]
8. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors. Huan Y; Jiang Q; Liu JL; Shen ZF J Pharmacol Toxicol Methods; 2015; 71():8-12. PubMed ID: 25464020 [TBL] [Abstract][Full Text] [Related]
9. Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity. Wang Y; Landheer S; van Gilst WH; van Amerongen A; Hammes HP; Henning RH; Deelman LE; Buikema H PLoS One; 2012; 7(10):e46781. PubMed ID: 23071636 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog. Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785 [TBL] [Abstract][Full Text] [Related]
11. Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats. Helmy MM; Mouneir SM Pharmacol Rep; 2019 Dec; 71(6):1133-1139. PubMed ID: 31675669 [TBL] [Abstract][Full Text] [Related]
12. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes. He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545 [TBL] [Abstract][Full Text] [Related]
13. Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD. Benetti A; Martins FL; Sene LB; Shimizu MHM; Seguro AC; Luchi WM; Girardi ACC Am J Physiol Renal Physiol; 2021 Mar; 320(3):F285-F296. PubMed ID: 33346727 [TBL] [Abstract][Full Text] [Related]
14. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. Wang A; Dorso C; Kopcho L; Locke G; Langish R; Harstad E; Shipkova P; Marcinkeviciene J; Hamann L; Kirby MS BMC Pharmacol; 2012 Apr; 12():2. PubMed ID: 22475049 [TBL] [Abstract][Full Text] [Related]
15. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Liu X; Men P; Wang Y; Zhai S; Liu G Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129 [TBL] [Abstract][Full Text] [Related]
16. Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin. Luippold G; Mark M; Klein T; Amann K; Daniel C Diabetes Res Clin Pract; 2018 Sep; 143():199-203. PubMed ID: 30031047 [TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647 [TBL] [Abstract][Full Text] [Related]
18. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice. Tebboth A; Lee S; Scowcroft A; Bingham-Gardiner P; Spencer W; Bolodeoku J; Hassan SW Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279 [TBL] [Abstract][Full Text] [Related]